NEW YORK (GenomeWeb News) – Wall Street analysts took a mixed view of Myriad Genetics today following the announcement on Friday by the US Supreme Court that it would review a lawsuit challenging the company's patents related to the BRCA1 and BRCA2 genes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.